Skip to main content
. 2011 May 11;36(9):1932–1939. doi: 10.1038/npp.2011.80

Table 2. Schematic Representation of a Testing day in Six Treatment Conditions.

0900 hours 0930 hours, T1 01000 hours, T2 01130 hours 01130–01300 hours
Arrival PLA PLA Vital-signs measurements and blood-sample collection Memory tests
  Ketanserin PLA    
  Pindolol PLA    
  PLA MDMA    
  Ketanserin MDMA    
  Pindolol MDMA    

During pre-treatment (T1) subjects received either placebo, ketanserin 50 mg or pindolol 20 mg. Treatment (T2) consisted of either MDMA 75 mg or placebo.